MEGHAN BYNUM: Open Payments
NPI 1699407080 · FREDERICKSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$868 in 39 payments from 16 companies in 2025. Trend: 2023 $27 · 2024 $290 · 2025 $868
Food & beverage: $868
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $162 |
| Ardelyx, Inc. | 3 | $90 |
| ABBVIE INC. | 3 | $67 |
| PFIZER INC. | 3 | $55 |
| QOL Medical, LLC | 2 | $51 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $44 |
| Lilly USA, LLC | 2 | $41 |
| Gilead Sciences, Inc. | 2 | $33 |
| GENZYME CORPORATION | 1 | $30 |
Products named: TREMFYA, ENTYVIO, IBSRELA, XELJANZ, Sucraid, XIFAXAN, OMVOH, DUPIXENT.
Industry payments across VA — which companies pay providers there.
